Pharmacological evaluation of a diarylmethylene-piperidine derivative: A new potent atypical antipsychotic?

Bioorganic and Medicinal Chemistry Letters

Volumn 11, Issue 10, 2001, Pages 1313-1316

  Talaga, Patrice ^a   Matagne, Alain ^a   Klitgaard, Henrik ^a  

^a UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; METHYLENE PIPERIDINE DERIVATIVE; NEUROLEPTIC AGENT; PIPERIDINE DERIVATIVE; SEROTONIN 2 RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; HYPERACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; RAT; RECEPTOR AFFINITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; MICE; PIPERIDINES; PROTEIN BINDING; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0035927196     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(01)00200-1     Document Type: Article

References (27)

1. Keith S.J. N. Engl. J. Med. 12:1997;851.
2. Armer R., Miller D.J. Idrugs. 3:2000;920.
3. Nakazato A., Okuyama S. Exp. Opin. Ther. Patents. 10:2000;75.
4. Kerwin R., Owen M. Br. J. Psychiatry. 174(Suppl. 38):1999;1.
5. Nakazato A., Okuyama S. Expert Opin. Ther. Patents. 10:2000;75.
6. McDonnel M.E., Reitz A. Expert Opin. Ther. Patents. 4:1994;1221.
7. Seeman P., Guan H.C., Van Tol H.H.M. Nature. 365:1993;441.
8. Seeman P. Neuropsychopharmacology. 7:1992;261.
9. Bersani G., Grispini A., Marimi S., Pasini A., Valducci M., Ciani N. Curr. Ther. Res. 40:1986;492.
10. Ceulemans D.L.S., Geldens Y.G., Hoppenbrouwers M.L., Reyntjens A.J.M., Janssen P.A.J. Psychopharmacology. 85:1985;329.
11. Mewshaw R.E., Abreu M.E., Silverman L.S., Mathew R.M., Tiffany C.W., Baily M.A., Karbon E.W., Ferkany J.W., Kaiser C.J. J. Med. Chem. 36:1993;3073.
12. Stockmeier C.A., Dicarlo J.J., Zhang Y., Thompson P., Melter H.Y. J. Pharmacol. Exp. Ther. 266:1993;1374.
13. Saller C.F., Salama A.I. Psychopharmacology. 112:1993;285.
14. Compound 2 was characterized by NMR, mass spectrometry, and HPLC. For experimental details see: Moldenhauer O., Trautman G., Pfluger R., Döser H. Justus Liebigs Ann. Chem. 580:1953;176.
15. Watanabe Y., Usui H., Kobayashi S., Yoshiwara H., Shibano T., Tanaka T., Morishima Y., Yasuoka M., Kanao M. J. Med. Chem. 35:1992;189.
16. Hydrogenation of 2,5-disubstituted furan derivatives usually gives the corresponding cis-derivative as described, for example, in: Eberbach W. In Houben-Weyl, Band E6a, Hetarene I, Teil 1; Georg Thieme Verlag: Stuttgart, New York, pp 16-166.
17. Leysen J.E., Janssen P.M.F., Schotte A., Luyten W.H.M.L., Megens A.H.P. Psychopharmacology. 112:1993;S40.
18. Roth B.L., Tandra S., Burgess L.H., Sibley D.R., Meltzer H.Y. Psychopharmacology. 120:1995;365.
19. 50 values for inhibition of climbing and stereotypy were calculated by non-linear regression analysis.
20. Hyperactivity was induced by sc administration of d-amphetamine sulfate at a dose of 4 mg/kg, 30 min before testing. Compounds were administered ip 30 min prior to d-amphetamine, using groups of eight mice. The minimal active dose, defined as the lowest dose which significantly (p<0.05) inhibited d-amphetamine induced hyperactivity, was calculated using the Mann-Whitney U-test (two-tailed).
21. A stereotyped behavior was induced by sc administration of d-amphetamine sulfate, at a dose of 12 mg/kg. Compounds were administered ip 30 min prior to d-amphetamine, using groups of eight mice. The minimal active dose, defined as the lowest dose which significantly (p<0.05) inhibited d-amphetamine induced stereotypy, was calculated using the Kolmogorov-Smirnov two sample test.
22. 50 values were calculated by non-linear regression analysis.
23. Induction of catalepsy was performed at Porsolt & Partners Pharmacology, France, according to standard procedures. The compounds were administered po in groups of six rats and the induction of catalepsy was examined at 30 min intervals up to 360 min.
24. Conditioned avoidance response inhibition was performed at Porsolt & Partners Pharmacology, France, using the Sidman avoidance test. Compounds were administered po in groups of eight trained rats for which stable baseline performance has been verified over 2 consecutive weeks. The number of avoidance responses, the number of shocks received and the number of escape failures were measured during a session of 20 min starting 60 min after dosing.
25. 50 values were calculated by non-linear regression analysis.
26. An Irwin test was performed according to a standard protocol after ip administration. Activities like onset of sedation, incidence of convulsion and lethality were selected to assess the neurotoxic profile of the compounds.
27. Meltzer H.Y., Matsubara S., Lee J.C. J. Pharmacol. Exp. Ther. 251:1989;238.